Clinical Trial: Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery

U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07674771) titled 'Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy Delivery' on June 24.

Brief Summary: The purpose of this study is to characterize the reduction in PSMA-avid tumor volume and metastasis-directed radiotherapy treatment intensity facilitated by PET PSMA-response adapted SABR for poly-metastatic castration sensitive prostate cancer.

Study Start Date: July 15

Study Type: INTERVENTIONAL

Condition: Castrate Sensitive Prostate Cancer Prostate Cancer Metastasis Castration Resistant Prostate Cancer(mCRPC)

Intervention: DRUG: Drug: 68-Ga PSMA11...